{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Subcutaneous+Lenacapavir", "query": { "intervention": "Subcutaneous Lenacapavir" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 13, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Subcutaneous+Lenacapavir&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T14:20:22.327Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06819176", "title": "Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Human Immunodeficiency Virus" ], "interventions": [ { "name": "Lenacapavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 50, "start_date": "2026-01-20", "completion_date": "2029-01-24", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-09-02T14:20:22.327Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06819176" }, { "nct_id": "NCT04150068", "title": "Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Oral Lenacapavir", "type": "DRUG" }, { "name": "Oral Lenacapavir Placebo", "type": "DRUG" }, { "name": "Subcutaneous Lenacapavir", "type": "DRUG" }, { "name": "Failing ARV Regimen", "type": "DRUG" }, { "name": "Optimized Background Regimen (OBR)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 72, "start_date": "2019-11-21", "completion_date": "2027-01", "has_results": true, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-09-02T14:20:22.327Z", "location_count": 35, "location_summary": "Los Angeles, California • Palm Springs, California • Sacramento, California + 28 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04150068" }, { "nct_id": "NCT07683000", "title": "Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Lenacapavir", "type": "DRUG" }, { "name": "Lenacapavir Tablet", "type": "DRUG" }, { "name": "Teropavimab", "type": "DRUG" }, { "name": "Zinlirvimab", "type": "DRUG" }, { "name": "SBR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2026-07-14", "completion_date": "2033-03", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-09-02T14:20:22.327Z", "location_count": 2, "location_summary": "Berkeley, Michigan • Annandale, Virginia", "locations": [ { "city": "Berkeley", "state": "Michigan" }, { "city": "Annandale", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07683000" }, { "nct_id": "NCT06970223", "title": "A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Cabotegravir long-acting", "type": "DRUG" }, { "name": "Lenacapavir long-acting", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2025-04-22", "completion_date": "2026-07-10", "has_results": false, "last_update_posted_date": "2025-11-28", "last_synced_at": "2026-09-02T14:20:22.327Z", "location_count": 1, "location_summary": "Long Beach, California", "locations": [ { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06970223" }, { "nct_id": "NCT06749054", "title": "Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Oral Lenacapavir", "type": "DRUG" }, { "name": "Subcutaneous Lenacapavir", "type": "DRUG" }, { "name": "Optimized Background Regimen (OBR)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "17 Years", "sex": "ALL", "summary": "Up to 17 Years" }, "enrollment_count": 12, "start_date": "2025-03-26", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-09-02T14:20:22.327Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06749054" }, { "nct_id": "NCT05729568", "title": "A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "Teropavimab", "type": "DRUG" }, { "name": "Zinlirvimab", "type": "DRUG" }, { "name": "Lenacapavir Tablet", "type": "DRUG" }, { "name": "Lenacapavir Injection", "type": "DRUG" }, { "name": "Antiretroviral Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 83, "start_date": "2023-05-15", "completion_date": "2030-12", "has_results": true, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-09-02T14:20:22.327Z", "location_count": 29, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 25 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05729568" }, { "nct_id": "NCT04811040", "title": "Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "Oral Lenacapavir", "type": "DRUG" }, { "name": "Subcutaneous Lenacapavir", "type": "DRUG" }, { "name": "Teropavimab", "type": "DRUG" }, { "name": "Zinlirvimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 32, "start_date": "2021-04-08", "completion_date": "2023-10-26", "has_results": true, "last_update_posted_date": "2025-01-27", "last_synced_at": "2026-09-02T14:20:22.327Z", "location_count": 23, "location_summary": "Los Angeles, California • Sacramento, California • San Diego, California + 19 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04811040" }, { "nct_id": "NCT04143594", "title": "Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Oral Lenacapavir", "type": "DRUG" }, { "name": "F/TAF", "type": "DRUG" }, { "name": "Subcutaneous Lenacapavir", "type": "DRUG" }, { "name": "TAF", "type": "DRUG" }, { "name": "BIC", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 183, "start_date": "2019-11-22", "completion_date": "2023-09-19", "has_results": true, "last_update_posted_date": "2024-10-02", "last_synced_at": "2026-09-02T14:20:22.327Z", "location_count": 49, "location_summary": "Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 40 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04143594" }, { "nct_id": "NCT07473778", "title": "Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Lenacapavir Injection", "type": "DRUG" }, { "name": "Emtricitabine/tenofovir disoproxil fumarate (F/TDF)", "type": "DRUG" }, { "name": "Emtricitabine/tenofovir alafenamide (F/TAF)", "type": "DRUG" }, { "name": "Cabotegravir (CAB)", "type": "DRUG" }, { "name": "Lenacapavir Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3000, "start_date": "2026-03-17", "completion_date": "2029-04", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-09-02T14:20:22.327Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07473778" }, { "nct_id": "NCT04925752", "title": "Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pre-Exposure Prophylaxis of HIV Infection" ], "interventions": [ { "name": "Oral Lenacapavir (LEN)", "type": "DRUG" }, { "name": "F/TDF", "type": "DRUG" }, { "name": "Sub-cutaneous (SC) Lenacapavir (LEN)", "type": "DRUG" }, { "name": "Placebo SC LEN", "type": "DRUG" }, { "name": "PTM F/TDF", "type": "DRUG" }, { "name": "PTM Oral LEN", "type": "DRUG" }, { "name": "F/TAF (for US participants only)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 3292, "start_date": "2021-06-28", "completion_date": "2028-08", "has_results": true, "last_update_posted_date": "2025-12-23", "last_synced_at": "2026-09-02T14:20:22.327Z", "location_count": 60, "location_summary": "Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 43 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04925752" } ] }